CP6679, a new injectable cephalosporin with broad spectrum and potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa

Journal of Infection and Chemotherapy

Volumn 8, Issue 2, 2002, Pages 138-144

  Ida, T ^a   Tsushima, M ^a   Ishii, T ^a   Atsumi, K ^a   Tamura, A ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Antibacterial activity; CP6679; MRSA; Pseudomonas aeruginosa

Indexed keywords

CEFOSELIS; CEFOTAXIME; CEFOZOPRAN; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CP 6679; IMIPENEM; PENICILLIN G; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; DRUG PROTEIN BINDING; GRAM NEGATIVE INFECTION; KLEBSIELLA PNEUMONIAE; LUNG INFECTION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS INFECTION; ANIMAL; DRUG EFFECT; INJECTION; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIOLOGICAL EXAMINATION; PENICILLIN RESISTANCE; STAPHYLOCOCCUS AUREUS;

ANIMALS; CEPHALOSPORINS; INJECTIONS; MALE; METHICILLIN RESISTANCE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS;

EID: 0036022485     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101560200024     Document Type: Article

References (23)

1. Nosocomial antimicrobial resistance surveillance
2. Bacterial resistance: A worldwide problem
3. Overview of resistance in the 1990s
4. Novel cephalosporin derivatives possessing a bicyclic heterocycle at the 3-position. Part I. Synthesis and biological activities of 3-(benzothiazol-2-yl)thiocephalosporin derivatives, CP0467 and related compounds
5. Novel cephalosporin derivatives possessing a bicyclic heterocycle at the 3-position. Part II. Synthesis and antibacterial activity of 3-(5-methylthiazolo[4,5-c]pyridinium-2-yl)thiomethylcephaslosporin derivatives and related compounds
6. CP6679, a new injectable cephalosporin. Part 1. Synthesis and structure-activity relationships
7. Role of an altered penicillin-binding protein in methicillin- and cephem-resistant Staphylococcus aureus
8. Synthesis and structure-activity relationships in the cefpirome series. I. 7[2-(2-aminothiazol-4-yl)-2-(Z)-oxyiminoacetamido]-3-[(substituted-1- pyridinio)methyl] ceph-3-em-4-carboxylates
9. Studies on condensed-heterocyclic azolium cephalosporins. IV. Synthesis and antibacterial activity of 7b-[2-(5-amino-1,2,4-thiadiazol-3-yl)-2(Z)-alkoxyiminoacetamido]-3- (condensed-heterocyclic azolium) methyl cephalosporins including SCE-2787
10. FK037, a new parenteral cephalosporin with a broad antibacterial spectrum. Synthesis and antibacterial activity
11. In vitro and in vivo antibacterial activities of E1077, a novel parenteral cephalosporin with a broad antibacterial spectrum
12. Characterization of eight β-lactamases of gram-negative bacteria
13. Excellent activity of FK037, a novel parenteral broad-spectrum cephalosporin, against methicillin-resistant staphylococci
14. TOC-39, a new parenteral broad-spectrum cephalosporin with excellent activity against methicillin-resistant Staphylococcus aureus
15. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a
16. Antimicrobial activity of SM-17466, a novel carbapenem antibiotic with potent activity against methicillin-resistant Staphylococcus aureus
17. In vitro activities of novel trans-3,5-disubstituted pyrrolidinylthio-1β-methylcarbapenems with potent activities against methicillin-resistant Staphylococcus aureus and Pseudomonas aeruginosa
18. β-lactam resistance in gram-negative bacteria: Global trends and clinical impact
19. ME1209 (CP6679), a new parenteral cephalosporin. II. In vitro and in vivo activity against P. aeruginosa
20. Mechanism of efficient elimination of protein D2 in outer membrane of imipenem-resistant Pseudomonas aeruginosa
21. Acquired carbapenemase
22. CP5068, a new carbapenem: In vitro and in vivo activities against MRSA
23. CP6679, a new injectable cephalosporin: II. In vitro antibacterial activity